- Home
- CHY vs IOVA Comparison
CHY vs IOVA Comparison
Compare CHY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHY
- IOVA
- Stock Information
- Founded
- CHY 2003
- IOVA 2007
- Country
- CHY United States
- IOVA United States
- Employees
- CHY N/A
- IOVA N/A
- Industry
- CHY Investment Managers
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHY Finance
- IOVA Health Care
- Exchange
- CHY Nasdaq
- IOVA Nasdaq
- Market Cap
- CHY 839.8M
- IOVA 975.1M
- IPO Year
- CHY N/A
- IOVA N/A
- Fundamental
- Price
- CHY $10.82
- IOVA $2.68
- Analyst Decision
- CHY
- IOVA Buy
- Analyst Count
- CHY 0
- IOVA 10
- Target Price
- CHY N/A
- IOVA $12.22
- AVG Volume (30 Days)
- CHY 128.3K
- IOVA 26.0M
- Earning Date
- CHY 01-01-0001
- IOVA 08-07-2025
- Dividend Yield
- CHY 10.11%
- IOVA N/A
- EPS Growth
- CHY N/A
- IOVA N/A
- EPS
- CHY N/A
- IOVA N/A
- Revenue
- CHY N/A
- IOVA $212,679,000.00
- Revenue This Year
- CHY N/A
- IOVA $86.62
- Revenue Next Year
- CHY N/A
- IOVA $69.13
- P/E Ratio
- CHY N/A
- IOVA N/A
- Revenue Growth
- CHY N/A
- IOVA 11070.12
- 52 Week Low
- CHY $9.97
- IOVA $1.64
- 52 Week High
- CHY $12.16
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- CHY 43.86
- IOVA 53.63
- Support Level
- CHY $10.88
- IOVA $1.70
- Resistance Level
- CHY $11.00
- IOVA $4.33
- Average True Range (ATR)
- CHY 0.12
- IOVA 0.40
- MACD
- CHY -0.03
- IOVA -0.01
- Stochastic Oscillator
- CHY 18.42
- IOVA 37.26
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.